{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:23:08Z","timestamp":1787844188230,"version":"build-2784847793"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Insulin resistance is one of the important underlying abnormalities of type 2 diabetes. The effect of thiazolidinedione on liver functions has been controversial in different studies. In this study, we evaluated the effect of rosiglitazone on liver enzymes in subjects with type 2 diabetes with and without abnormal liver function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Seventy-three patients with type 2 diabetes taking rosiglitazone 4 mg daily were enrolled in this 3-month study. Forty-two of them had normal liver function (NLF), and 31 had abnormal liver function (ABLF). Blood biochemistries were collected monthly during the treatment period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At baseline, other than age and liver enzymes, there were no differences in body mass index, fasting plasma glucose, hemoglobin A1c (HbA1c), and lipid profiles between the NLF and ABLF groups. At the end of the treatment, HbA1c was lowered in both groups, but only significantly in the ABLF group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.027). More importantly, serum concentrations of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the ABLF group decreased significantly (AST: 57.8 \u00b1 26.5 to 47.5 \u00b1 20.2 U\/L,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006; ALT 66.6 \u00b1 35.0 to 51.9 \u00b1 23.5 UL,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.004), while in the NLF group, a similar change was not found.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>After 3-month rosiglitazone treatment in subjects with type 2 diabetes with mildly elevated liver enzymes, significant improvement in AST and ALT were observed. Our study provides some hints that rosiglitazone might not be contraindicated in subjects with diabetes with abnormal liver function as previously thought, but further well-designed studies are necessary to clarify this issue.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/0253-7613.96340","type":"journal-article","created":{"date-parts":[[2012,5,17]],"date-time":"2012-05-17T14:28:31Z","timestamp":1337264911000},"page":"372-376","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes"],"prefix":"10.4103","volume":"44","author":[{"given":"Jing-Quan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Lin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Hsien","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsan-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pao-Ying","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiunn-Diann","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20260529","doi-asserted-by":"crossref","first-page":"61","DOI":"10.7326\/0003-4819-134-1-200101020-00014","article-title":"Nonhypoglycemic effects of thiazolidinediones","volume":"134","author":"Parulkar","year":"2001","journal-title":"Ann Intern Med"},{"key":"R2-17-20260529","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-2036.2005.02682.x","article-title":"The Treatment of Non-Alcoholic Steatohepatitis With Thiazolidinediones; Review Article","volume":"22","author":"Henrion","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R3-17-20260529","doi-asserted-by":"crossref","first-page":"118","DOI":"10.7326\/0003-4819-132-2-200001180-00005","article-title":"Hepatic failure in a patient taking rosiglitazone","volume":"132","author":"Forman","year":"2000","journal-title":"Ann Intern Med"},{"key":"R4-17-20260529","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7326\/0003-4819-132-2-200001180-00006","article-title":"Hepatocellular injury in a patient receiving rosiglitazone.A case report","volume":"132","author":"Al-Salman","year":"2000","journal-title":"Ann Intern Med"},{"key":"R5-17-20260529","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/00004836-200205000-00021","article-title":"Rosiglitazone-induced granulomatous hepatitis","volume":"34","author":"Dhawan","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"R6-17-20260529","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0002-9343(01)00926-3","article-title":"Liver failure in a patient treated with long-term rosiglitazone therapy","volume":"111","author":"Gouda","year":"2001","journal-title":"Am J Med"},{"key":"R7-17-20260529","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1023\/A:1015895925374","article-title":"Severe cholestatic hepatitis caused by thiazolidinediones: Risks associated with substituting rosiglitazone for troglitazone","volume":"47","author":"Bonkovsky","year":"2002","journal-title":"Dig Dis Sci"},{"key":"R8-17-20260529","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1463-1326.2004.00382.x","article-title":"Comparison of pioglitazone with other antidiabetic drugs for associated incidence of liver failure: No evidence of increased risk of liver failure with pioglitazone","volume":"7","author":"Rajagopalan","year":"2005","journal-title":"Diabetes Obes Metab"},{"key":"R9-17-20260529","first-page":"1008","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone","volume":"38","author":"Neuschwander-Tetri","year":"2003","journal-title":"Hepatology"},{"key":"R10-17-20260529","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0929-6646(09)60202-3","article-title":"Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease","volume":"105","author":"Wang","year":"2006","journal-title":"J Formos Med Assoc"},{"key":"R11-17-20260529","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0197-2456(90)90005-M","article-title":"Power and sample size calculations.A review and computer program","volume":"11","author":"Dupont","year":"1990","journal-title":"Control Clin Trials"},{"key":"R12-17-20260529","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2337\/diacare.25.5.815","article-title":"Evaluation of liver function in type 2 diabetic patients during clinical trials: Evidence that rosiglitazone does not cause hepatic dysfunction","volume":"25","author":"Lebovitz","year":"2002","journal-title":"Diabetes Care"},{"key":"R13-17-20260529","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/dmrr.1070","article-title":"Relationship between insulin resistance, inflammation and liver cell apoptosis in patients with severe obesity","volume":"26","author":"Civera","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"R14-17-20260529","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1146\/annurev-physiol-021909-135846","article-title":"Macrophages, inflammation, and insulin resistance","volume":"72","author":"Olefsky","year":"2010","journal-title":"Annu Rev Physiol"},{"key":"R15-17-20260529","first-page":"4","article-title":"Recent advances in the relationship between obesity, inflammation, and insulin resistance","volume":"17","author":"Bastard","year":"2006","journal-title":"Eur Cytokine Netw"},{"key":"R16-17-20260529","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/gut.50.5.585","article-title":"Non-alcoholic steatohepatitis (NASH): Where are we now and where are we going?","volume":"50","author":"Day","year":"2002","journal-title":"Gut"},{"key":"R17-17-20260529","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes","volume":"51","author":"Mayerson","year":"2002","journal-title":"Diabetes"},{"key":"R18-17-20260529","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.it.2003.10.013","article-title":"Inflammation: The link between insulin resistance, obesity and diabetes","volume":"25","author":"Dandona","year":"2004","journal-title":"Trends Immunol"},{"key":"R19-17-20260529","doi-asserted-by":"crossref","first-page":"E485","DOI":"10.1152\/ajpendo.00080.2006","article-title":"Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance","volume":"292","author":"Todd","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"R20-17-20260529","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1038\/oby.2002.137","article-title":"Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients","volume":"10","author":"Carey","year":"2002","journal-title":"Obes Res"},{"key":"R21-17-20260529","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0006-291X(03)00418-2","article-title":"PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: Suppression of TNF alpha secretion is not mediated by PTEN regulation","volume":"303","author":"Hong","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"R22-17-20260529","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1007\/s10620-007-9756-x","article-title":"Rosiglitazone attenuates liver inflammation in a rat model of nonalcoholic steatohepatitis","volume":"52","author":"Tahan","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R23-17-20260529","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00125-004-1503-7","article-title":"Rosiglitazone ameliorates insulin resistance in brown adipocytes of Wistar rats by impairing TNF-alpha induction of p38 and p42\/p44 mitogen-activated protein kinases","volume":"47","author":"Hernandez","year":"2004","journal-title":"Diabetologia"},{"key":"R24-17-20260529","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.metabol.2004.05.019","article-title":"The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus","volume":"54","author":"Jung","year":"2005","journal-title":"Metabolism"},{"key":"R25-17-20260529","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"R26-17-20260529","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/34178","article-title":"The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation","volume":"391","author":"Ricote","year":"1998","journal-title":"Nature"},{"key":"R27-17-20260529","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1210\/jc.2003-032103","article-title":"Evidence for a potent antiinflammatory effect of rosiglitazone","volume":"89","author":"Mohanty","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R28-17-20260529","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1164\/rccm.200207-740OC","article-title":"Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages","volume":"169","author":"Asada","year":"2004","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Indian Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363791-201244030-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:13:44Z","timestamp":1787843624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363791-201244030-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.4103\/0253-7613.96340","relation":{},"ISSN":["0253-7613"],"issn-type":[{"value":"0253-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}